NeuroMab™ Anti-Transferrin Receptor Antibody, Clone NR57P

Figure 1 depicts FACS analysis of mouse hybridoma parental clone supernatants binding to human and macaque TfR transiently expressed in 293 cells in the presence of 1 μM human holo-Tf.

The displayed result is a titration of 5 concentrations. 1: Monomer, free N-terminal, 4.2 mg/mL, never thawed; 2: Monomer, His-tagged N-terminal, 4.8 mg/mL; 3: Dimer, free N-terminal, 1.6 mg/mL.

Figure 2 depicts the binding of hu7A4.v15, hu15G11.v5 and hu7G7.v1 to huTfR in the presence of 6.3 μM holo-Tf.

Antibody binding to immobilized huTfR is shown in the presence (open symbols and dashed lines) or absence (closed symbols and solid lines) of 6.3 μM holo-Tf.

Figure 3 depicts the results of HFE-HuTfR binding and HFE blocking assays.

Binding of antibodies to increasing concentrations of huTfR captured by immobilized HFE. Figure 6B shows the binding of huTfR to immobilized HFE with increasing antibody concentration.

Figure 4 depicts the results of HFE-HuTfR binding and HFE blocking assays.

Binding of huTfR to immobilized HFE at increasing antibody concentrations.

Figure 5 depicts the results of experiments evaluating the effect of effector functional status on ADCC activity of anti-human TfR ("anti-hTFR") antibodies in primary human myelomonocytic or human erythroblastoid cell lines.

Binding of huTfR to immobilized HFE at increasing antibody concentrations.

Figure 6 depicts the experimental brain antibody concentrations.

The graph shows individual anti-TfR1/BACE1 , anti-TfR2/BACE1 , anti-gD and anti-BACE1 antibody concentrations in different brain regions 24 hours after dosing.

Figure 7 Pharmacodynamic results of cynomolgus monkey experiment.

The sAPPβ/sAPPα ratio changes over time.